Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

MEDI: Financial results for the third quarter and YTD September 2025 for Medistim ASA

Medistim
Another strong quarter for sales revenues with 25.7 % growth, ending at MNOK
166.8 (MNOK 132.8). Record sales revenue year to date September with 25.8 %
growth, ending at MNOK 517.5 (MNOK 411.5). Currency neutral sales of own
products were up 29.8 % for the quarter and 28.0 % year to date September.

Strong currency neutral growth for the quarter in AMERICAS and APAC, up 35.7 %
and 194 % respectively. EMEA down 11.8 %, yet up 1 % year to date September.

Third-party distributor sales in Scandinavia increased 4.4 % for the quarter and
16.2 % year to date September.

Operating profit (EBIT) grew by 27.1 % for the quarter and ended at MNOK 40.6,
resulting in 24.3 % EBIT margin (MNOK 31.9, 24.0 % margin). Year to date
September profit grew 46.2 % ending at a record MNOK 153.9, and 29.7 % EBIT
margin (MNOK 105.2, 25.6 % margin).

Recurring sales remained high, but strong capital sales reduce recurring sales
in % to 69.3% (73.7 %) compared to YTD September last year.

Solid cash position at quarter end with MNOK 157.6 after paying a dividend of
NOK 6.00 per share (NOK 4.5), total MNOK 109.5 in May (MNOK 82.4). No
interest-bearing
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.